Speaker
Description
Under CTBT, an On-Site Inspection (OSI) is the final measure to verify compliance with the Treaty and can be used to verify whether a suspicious event was, in fact, a nuclear explosion. But that measurement tends to get a false detection from medical radioisotope production released Xenon. CTBTO commits to limit the released Xenon to 9 Gbq/day but the medical radioisotope producer (MRP) should not reduce its production because of the medical radioisotope demand and for business profit needs. It has been an unsolved dilemma between CTBTO and the MRP. A business approach is one of the choices for this dilemma. The concept is there must be a company that will buy and utilize the released Xenon from MPR. As we know, Xenon-135 can be used in medical or other industry needs. So, the released Xenon can be re-commercialized. This concept is expected to offer a solution for the false-detection of nuclear weapon test from CTBTO and engage the medical radioisotope production for fulfilling the world demand. The further research that we must do is about an effective technology for transferring the Xenon from the MRP to Xenon based industry company.
